Glycolysis in cancer: A potential target for therapy

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1358-1366

  Gatenby, Robert A ^a   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aerobic glycolysis; Cancer; Glucose uptake; Treatment

Indexed keywords

APIGENIN; BROMOPYRUVIC ACID; DEOXYGLUCOSE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GELDANAMYCIN; GLUCOSE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; JASMONIC ACID METHYL ESTER; LONIDAMINE; PACLITAXEL; PYRUVIC ACID DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ACIDOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG MECHANISM; GLIOBLASTOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LUNG NON SMALL CELL CANCER; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; SHORT SURVEY; TUMOR CELL;

ANOXIA; GLUCOSE; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 34447094919     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.03.021     Document Type: Short Survey

References (68)

1. Abbey C.K., Borowsky A.D., Gregg J.P., Cardiff R.D., and Cherry S.R. Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J Mammary Gland Biol Neoplasia 11 (2006) 137-149
2. Abbey C.K., Borowsky A.D., McGoldrick E.T., Gregg J.P., Maglowsky J.E., Cardiff R.D., et al. In vivo PET imaging of progression of transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA 101 (2004) 11438-11443
3. Boren J., Cascante M., Marin S., Comin-Anduix B., Centelles J.J., Lim S., et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 276 (2001) 37747-37753
4. Burke B., Giannoudis A., Corke K.P., Gill D., Wells M., Ziegler-Heitbrock L., et al. Hypoxia-induced gene expression in human macrophages: Implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163 (2003) 1233-1243
5. Cao X., Fang L., Gibbs S., Huang Y., Dai Z., Wen P., et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemo Pharm 59 (2007) 495-505
6. Chen C., Pore N., Behrooz A., Isnail-Beigi F., and Maity A. Regulation of glut 1 mRNA by hypoxia-inducible factor-1 Interaction between H-ras and hypoxia. J Biol Chem 276 (2001) 9519-9525
7. Cramer T., Yanabishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
8. Cuvier C., Jang A., and Hill R.P. Exposure to hypoxia, glucose starvation and acidosis: Effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 15 (1997) 19-25
9. DeLena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L., et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer A phase II study. Eur J Cancer 37 (2001) 364-368
10. Di Cosimo S., Ferreti G., Papaldo P., Carlini P., Fabi A., and Cognetti F. Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today 39 (2003) 157-174
11. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
12. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.H. Apigenein inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19 (2005) 342-353
13. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
14. Floridi A., Bruno T., Miccadei S., Fanciulli M., Federico A., and Paggi M.G. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 56 (1998) 841-849
15. Floridi A., Paggi M.G., Marcante M.L., Silvestrini B., Caputo A., and De Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66 (1981) 497-499
16. Gambhir S.S. Molecular imaging of cancer with positron emission tomorgraphy. Nat Rev Cancer 2 (2002) 891-899
17. Gatenby R.G., and Gawlinski E.T. A reaction-diffusion model of cancer invasion. Cancer Res 56 (1996) 5745-5753
18. Gatenby R.A., Gawlinski E.T., Gmitro A.F., Kaylor B., and Gillies R. Acid-mediated tumor invasion: A multidisciplinary study. Cancer Res 66 (2006) 5216-5223
19. Gatenby R.A., Gawlinski E.T., Tangen C.M., Flanigan R.C., and Crawford E.D. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 62 (2002) 5218-5222
20. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 (2004) 891-899
21. Gatenby R.A., Maini P., and Gawlinski E. Analysis of tumor as an inverse problem provides a novel theoretical framework for understanding tumor biology and therapy. Appl Math Lett 15 (2000) 339-345
22. Gatenby R.A., and Vincent T.L. An evolutionary model of carcinogenesis. Cancer Res 63 (2003) 6212-6220
23. Gatenby R.A., Vincent T., and Gillies R. Evolutionary dynamics in carcinogenesis. Math Models Methods Appl Sci 15 (2005) 1-20
24. Georger B., Kerr K., Tang C.H., Fung K.M., Powell B., Sutton L.M., et al. Antitumor activity of rapamycin analog CCI [779] in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61 (2001) 1527-1532
25. Gerschwind J.F., Georgiades C.S., Ko Y.H., and Pedersen P.L. Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62 (2002) 3909-3913
26. Gillies R.J., Raghunand N., Karczmar G.S., and Bhujwalla Z.M. MRI of the tumor microenvironment. J Magn Reson Imaging 16 (2002) 430-450
27. Gottschalk S., Anderson N., Hainz C., Eckhjardt S.G., and Serkova N.J. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10 (2004) 6661-6668
28. Greijer A.E., van der Groep P., Kemming D., Shvarts A., Smezna G.L., Meijer G.A., et al. Up-regulation of gene expression of by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206 (2005) 291-304
29. Harguindey S., Henderson E.S., and Naeher C. Effects of systemic acidification of mice with Sarcoma 180. Cancer Res 39 (1979) 4364-4371
30. Heyfets A., and Flescher E. Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Lett (2006)
31. Homem de Bittencourt P.I., Peres C.M., Yano M.M., Hiratea M.H., and Curi R. Pyruvate is a lipid precursor for rat lymphocytes in culture: Evidence for a lipid exporting capacity. Biochem Mol Biol Int 30 (1993) 631-641
32. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 26 (2003) 577-590
33. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., et al. AMP-activated protein kinase induces a p53-dependent metabolic switch. Mol Cell 18 (2005) 283-293
34. Kelley S.T., Manon C., Buerk D.G., Bauer T.W., and Fraker D.L. Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery 132 (2002) 252-258
35. Kim J., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
36. Ko Y.H., Pederson P.L., and Gerschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 173 (2001) 83-91
37. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., et al. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 3 (2004) 269-275
38. Kondoh H., Lieonart M.E., Bernard D., and Gil J. Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol Histopathol 22 (2007) 85-90
39. Kondoh H., Lieonart M.E., Gil J., Beach D., and Peters G. Glycolysis and cellular immortalization. Drug Discov Today 2 (2005) 263-267
40. Lee K., Roth R.A., and Lapress J.J. Hypoxia, drug therapy and toxicity. Pharmacol Ther (2006)
41. Lyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., et al. Cellular and developmental control of homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
42. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via proteosome pathway in prostate cancer cells. Cancer Res 62 (2003) 2478-2482
43. Macpherson G.R., and Figg W.D. Small molecule mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol Ther 3 (2004) 503-504
44. Martin D.S., Spriggs D., and Koutcher J.A. A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis 6 (2001) 125-131
45. Maschek G., Savaraj M., Priebe W.S., Braunschweiger P., Hamilton K., Tidmarsh G.F., et al. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64 (2004) 31-34
46. Osada M., Imaoka S., and Funae Y. Apigenin suppresses the expression of VEGF, and important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett 575 (2004) 59-63
47. Oudard S., Carpentier A., Banu E., Fauchon F., Celerier D., Poupon M.F., et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. Neurooncology 63 (2003) 81-86
48. Papaldo P., Lopez M., Cortesi E., Cammilluzzi E., Antimi M., Terzoli E., et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21 (2003) 3462-3468
49. Park H.J., Lyons J.C., Ohtsubo T., and Song C.W. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 80 (1990) 1892-1897
50. Raghunand N., Gatenby R.A., and Gillies R.J. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76 (2003) S11-S22
51. Rohzin J., Sameni M., Ziegler G., and Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54 (1994) 6517-6525
52. Rotem R., Heyfets A., Fingrut O., Blickstein D., Shaklai M., and Flescher E. Jasmonates: Novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65 (2005) 1984-1993
53. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
54. Sang N., Stiehl D.P., Bohensky J., Leshchinsky V., and Sriinivas J.C. MAPK signaling up-regulated the activity of hypoxia-inducible factor by its effects on p300. J Biol Chem 278 (2003) 14013-14019
55. Semenza G. Targeting HIF-1 for cancer therapy. Nature 3 (2003) 721-731
56. Serkova N., and Boros L.G. Detection of resistance to imatinib by metabolic profiling: Clinical and drug development implications. Am J Pharmacogenomics 5 (2005) 293-302
57. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181 (2005) 507-514
58. Telang S., Yalcin A., Clem A.L., Bucala R., Lane A.N., Eaton J.W., et al. Ras transformation requires metabolic control of 6-phophofructo-2-kinase. Oncogene 25 (2006) 7225-7234
59. Vangellur A., Phillips J.M., Bogenesch J.B., and LaPres J.J. Gene expression profiling of hypoxia signaling in human hepatocelluar carcinoma cells. Phys Genom 22 (2005) 308-318
60. Varshney R., Dwarakanath B., and Jain V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-d-glucose in human cancer cells. Int J Radiat Biol 81 (2005) 397-408
61. Vengellur A., Woods B.G., Ryan H.E., Johnson R.S., and LaPres J.J. Gene expression profiling of the hypoxia signaling pathway in hypoxia inducible factor 1 α null mouse embryonic fibroblasts. Gene Exp 11 (2003) 181-197
62. Warburg O. The metabolism of tumours (1930), Constable Press, London
63. Williams A.C., Collard T.J., and Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis. Oncogene 16 (1999) 3199-3204
64. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., et al. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65 (2005) 613-621
65. Yashiro M., Carethers J.M., Laghi L., Saito K., Slezak P., Jaramilo E., et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 61 (2001) 2672-2683
66. Yasuda S., Fuji H., Nakahara T., Nishiumi N., Takahashi W., Ide M., et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 42 (2001) 989-992
67. Yuan J., Narayanan L., Rockwell S., and Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60 (2000) 4372-4376
68. Zhang X.D., Deslande E., Villedieu M., Poulain L., Duval M., Gauduchon P., et al. Effect of 2-deoxy-d-glucose on various malignant cell lines in vitro. Anticancer Res 26 (2006) 3561-3566